ORGO Hits 22% After Hours On FDA Meeting — Regulatory Pathway Opens

What Sextant Sees

GSS: 68 | Resonance: 35 | Tension: condensing
Active Patterns: FOMO Ignition, Wrong Consensus Meets Deadline, The Compression Signal
Theoretical: The Tidal Wave
Dimensions: M:9.8 C:6.2 D:3 S:6 CP:1 Mg-Q:8 Mg-T:7
Velocity: gaining: C_options_anomaly +7, C_options_put_ratio +3 (7 scans)

The Chokepoint

They control the bioerodible placental tissue supply chain. Advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds — not easily replicated. Direct sales force reaches hospitals, wound centers, government facilities, and physician offices. Manufacturing placental tissue products requires donor sourcing, processing, and regulatory expertise that creates barriers to entry.

Why It Flagged Today

ORGO compression signaling matched with regulatory momentum. Shares of Organogenesis Holdings Inc. (ORGO) jumped 22% in Monday's extended trading hours after the company said that it met with the U.S. Food and Drug Administration (FDA), and now plans to initiate seeking approval for its experimental treatment ReNu before the end of December. The treatment received FDA's Regenerative Medicine Advanced Therapy (RMAT)-designation in 2021. The company is seeking approval for ReNu in the treatment of knee osteoarthritis pain, a degenerative joint disease that is estimated to affect nearly 31.1 million Americans. The scanner sees high short interest (10% of float), oversold RSI, and analyst coverage gaps aligning with breaking regulatory news.

Watch For

May 7, 2026 first quarter earnings call. Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that first quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, May 7th. Rolling BLA submission updates before December 2026 matter more than quarterly numbers.

The Asymmetry

Upside: ReNu approval could unlock $500M+ addressable market for knee osteoarthritis pain in patient population exceeding 31 million Americans. Downside: Revenue concentration in wound care makes company vulnerable to Medicare reimbursement changes and competitive pricing pressure.

Full entry window, exit conditions, and score trajectory available to Pro members at damonskyeresearch.com